Emergent BioSolutions Inc - Company Profile
Powered by 
All the data and insights you need on Emergent BioSolutions Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Emergent BioSolutions Inc Strategy Report
- Understand Emergent BioSolutions Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Emergent BioSolutions Inc (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent's pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
400 Professional Dr, Suite 400, Gaithersburg, Maryland, 20879
Website
emergentbiosolutions.com
Telephone
1 240 6313200
No of Employees
1,600
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EBS (NYSE)
Revenue (2022)
$1.0B
-6.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-259.4%
(2022 vs 2021)
Market Cap*
$107.5M
Net Profit Margin (2022)
XYZ
-282.7%
(2022 vs 2021)
* As of and is in US$
Emergent BioSolutions Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| BioThrax - Anthrax Vaccine | ACAM2000 |
| ACAM2000 - Smallpox (Vaccinia) Vaccine | Anthrasil |
| Anthrasil - Inhalational Anthrax | Bat |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company signed a contract worth US$235.8 million with the U.S. Department of Defense to supply BioThrax. |
| 2023 | New Product Approvals | In August, the company launches NARCAN, is a Nasal Spray Over the Counter to help save a life from an opioid overdose emergency. |
| 2023 | Corporate Changes/Expansions | In August, the company announces strategic expansions to strengthen its core business and financial position. |
Competitor Comparison
| Key Parameters | Emergent BioSolutions Inc | Merck & Co Inc | Novartis AG | GSK plc | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United Kingdom | United States of America |
| City | Gaithersburg | Kenilworth | Basel | Brentford | Thousand Oaks |
| State/Province | Maryland | New Jersey | - | England | California |
| No. of Employees | 1,600 | 72,000 | 76,057 | 70,212 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zsolt Harsanyi, Ph.D. | Chairman | Executive Board | 2022 | 79 |
| Joseph C. Papa | President; Chief Executive Officer | Senior Management | 2024 | - |
| Richard S. Lindahl | Chief Financial Officer; Treasurer; Executive Vice President | Senior Management | 2018 | 59 |
| Adam R. Havey | Executive Vice President; Chief Operating Officer | Senior Management | 2021 | 52 |
| Michelle Pepin | Chief Human Resources Officer; Senior Vice President | Senior Management | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward